CHRM1 and myasthenia gravis: Based on the results of docking studies, the main ingredients, including isobrucine, vomicine, (s)-stylopine, strychnine, brucine-N-oxide, and brucine, were anticipated to bind to and regulate the function of AKT1, MAPK1, MAPK14, CHRM1, ACHE, or CHRNA4, which could be related targets for the treatment of MG.